Evidence record · ER-ARA290-NEUROPATHY-026
Does ARA-290 reduce sarcoidosis-associated neuropathy symptoms?
ARA-290 reduces neuropathic symptoms in sarcoidosis-associated small-fibre neuropathy
ARA-290 produced symptom and small-fibre signals in small exploratory studies of sarcoidosis-associated small-fibre neuropathy. This supports a limited finding in that narrow population, but the programme is too small for a dependable routine-treatment conclusion. It does not establish benefit for general neuropathy, pain or recovery.
Claim boundary
What this verdict covers
The verdict is confined to adults with sarcoidosis-associated small-fibre neuropathy and the outcomes measured in early trials. It does not transfer to other neuropathies.
- Compound
- ARA-290 or cibinetide
- Population
- Adults with sarcoidosis-associated small-fibre neuropathy
- Outcome
- Neuropathy symptoms and small-fibre measures
- Record ID
- ER-ARA290-NEUROPATHY-026
Evidence synthesis
What the research can support
A pilot study and subsequent blinded work reported improvements in some symptom measures and corneal nerve-fibre outcomes. Samples were small, several outcomes were exploratory and not every measure separated clearly from placebo.
Why the confidence is low
Small trials give imprecise estimates and are vulnerable to selective outcome interpretation. Larger independent replication and longer safety follow-up are needed.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-ARA290-NEUROPATHY-026 addresses one bounded question: Does ARA-290 reduce sarcoidosis-associated neuropathy symptoms?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Limited human, the verdict is Supported and confidence is Low. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| ARA-290 pilot study in sarcoidosis neuropathy | The pilot reported symptom signals in a small selected population. | A pilot cannot establish routine effectiveness. | 10 August 2026 |
| Randomised ARA-290 study | The study reported symptom and corneal-nerve findings in sarcoidosis-associated neuropathy. | The small programme does not generalise to all neuropathy. | 10 August 2026 |
| Clinical trial registry record | The registry documents protocol and outcome planning for clinical development. | A registry record does not replace published results. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on ARA-290 or cibinetide for this claim?
The verdict is supported for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
A pilot study and subsequent blinded work reported improvements in some symptom measures and corneal nerve-fibre outcomes. Samples were small, several outcomes were exploratory and not every measure separated clearly from placebo. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is ARA-290 or cibinetide authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Athletes should check the current WADA Prohibited List and obtain sport-specific advice. An experimental or non-approved peptide may fall within the S0 category even when it is not named individually. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What could change this verdict?
A larger multicentre randomised trial with a prespecified primary clinical outcome, disease-specific comparator, adequate duration and independent replication. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation